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Several pathways and pathologies have been suggested as connections between obesity and diabetes,
including inflammation of adipose and other tissues, toxic lipids, endoplasmic reticulum stress, and fatty
liver. One specific proposal is that insulin resistance induces a vicious cycle in which hyperinsulinemia
increases hepatic lipogenesis and exacerbates fatty liver, in turn further increasing insulin resistance. Here
I suggest that reversing this cycle via suppression of the lipogenic transcription factor SREBP-1c is a common
thread that connects the antidiabetic effects of a surprising number of nuclear hormone receptors, including
CAR, LRH-1, TRb, ERa, and FXR/SHP.The diverse members of the nuclear receptor superfamily exert
a wide range of metabolic regulatory effects. Within the context
of insulin resistance and type 2 diabetes, the best knownmay be
the classic hyperglycemic and diabetogenic effects of glucocor-
ticoids (Ingle, 1941; Ingle et al., 1945; Long et al., 1940; Munck,
1971), and GR has been found more recently to directly downre-
gulate key components of the insulin signaling cascade (Rose
et al., 2010). Glucorticoids can be produced outside the adrenal,
and local production by visceral adipose tissue is thought to be
a contributor to insulin resistance in obesity (Gathercole and
Stewart, 2010). In the liver, glucocorticoid excess promotes
steatosis (Rose et al., 2010), and glucocorticoids have emerged
more recently as modulators of additional hepatic metabolic
pathways, including bile acid homeostasis (Rose et al., 2011).
Activation of the oxysterol receptors LXRa and LXRbmay also
have negative effects, since they are well known inducers of
hepatic lipogenesis and fatty liver, and double knockouts do
not become insulin resistant when fed a high-fat diet (Kalaany
et al., 2005; Kalaany and Mangelsdorf, 2006). They are essential
for the activation of SREBP-1c expression by insulin (Horton
et al., 2002; Repa et al., 2000; Yoshikawa et al., 2001), and the
elevated expression of LXRa observed in human subjects with
nonalcoholic fatty liver disease (NAFLD) is correlated with in-
creased expression of SREBP-1c and its downstream lipogenic
targets (Higuchi et al., 2008). However, synthetic LXR agonists
can have antidiabetic effects in some cases (Cao et al., 2003;
Commerford et al., 2007; Grefhorst et al., 2005; Herzog et al.,
2007; Laffitte et al., 2003; Liu et al., 2006). Such effects have
been attributed to promotion of peripheral glucose uptake,
particularly by inducing Glut4 expression in adipose tissues,
and suppression of hepatic gluconeogenesis via repression of
hepatic GR and gluconeogenic gene expression.
The bile acid receptor FXR may also have conflicting effects in
different contexts. Loss of FXR results in steatosis (Sinal et al.,
2000) and insulin resistance (Ma et al., 2006; Zhang et al., 2006)
inmice fednormal chow,and thereare reportsofbeneficial effects
of both bile acids and synthetic FXR ligands on insulin sensitivity
(Cipriani et al., 2010; Sanyal et al., 2009; Watanabe et al., 2006;
Zhang et al., 2006). However, FXRdeficiency reportedly improves
glucose homeostasis in mouse models of obesity (Prawitt et al.,2011), and long-term FXR activation via a synthetic agonist
induces obesity and insulin resistance, perhaps via suppression
of endogenous bile acid pools (Watanabe et al., 2011).
In contrast to these diabetogenic effects, activation of surpris-
ingly large number of other nuclear receptors has beneficial
effects on insulin sensitivity (Table 1). Some, such as the antidi-
abetic actions of agonist ligands for PPARg and PPARa, are very
well recognized (Lalloyer and Staels, 2010; Lehrke and Lazar,
2005). Others are less so, including the clear beneficial impact
of estrogen receptor activation (Mauvais-Jarvis, 2011), and the
well-documented insulin-sensitizing effects of phenobarbital in
human type 2 diabetes (Lahtela et al., 1985; Sotaniemi and
Karvonen, 1989). The beneficial impact of HNF-4a is revealed
by the genetic consequences of its mutation in human patients
with mature onset diabetes of the young type 1 (MODY-1)
(Vaxillaire and Froguel, 2008), and also in mice with b cell-
specific deletion of HNF-4a (Gupta et al., 2005; Miura et al.,
2006). The potential antidiabetic effects of vitamin D in human
patients remain controversial (Takiishi et al., 2010). Finally, there
are reports of antidiabetic effects of specific RXR agonists
(Pinaire and Reifel-Miller, 2007), although it remains unclear
whether these effects are due to activation of RXR alone or a het-
erodimer. All-trans retinoic acid treatment can also have positive
metabolic effects in mice, including weight loss and improved
glucose tolerance (Amengual et al., 2010; Berry and Noy, 2009;
Manolescu et al., 2010), suggesting that one or more of the
retinoic acid receptor (RAR) isoforms could exert antidiabetic
effects. More broadly, however, retinoids are associated with
negative effects in humans (Gerber and Erdman, 1982), and
the association of distinct components of the vitamin A-retinol-
eetinoic acid axis with insulin sensitivity is both complex and
contradictory. Thus, while specific antidiabetic effects may exist,
none of the six retinoid receptors are included in the table.
Overall, however, it is clear that activation of a remarkably
large number of nuclear receptors improves insulin sensitivity.
This striking functional convergence raises a simple question:
despite their very diverse physiologic roles, does a common
mechanistic thread connect their antidiabetic effects?
Twenty years ago, the late Denis McGarry provocatively sug-
gested that dysregulation of fatty acid metabolism is moreCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 615
Table 1. Diverse Impact of Nuclear Receptors on Insulin
Resistance
Mouse Models Human Patients
GR – –
LXRa/b +/ ?
FXR +/ +?
PPARa/g/d +/+/+ +/+/?
ERa/b + +
CAR + +
HNF-4a +* +*
VDR + ?
TRb + ?
LRH-1 + ?
NR4A1-3 + ?
+, significant evidence for antidiabetic effects; –, evidence for deleterious
effects; ?, no evidence, or suggestive but inconclusive evidence. PPARs
(Barish et al., 2006; Lalloyer and Staels, 2010; Lehrke and Lazar, 2005),
ERa (Bryzgalova et al., 2008b; Mauvais-Jarvis, 2011), CAR (Dong et al.,
2009; Lahtela et al., 1985; Sotaniemi and Karvonen, 1989), FXR (Cipriani
et al., 2010; Sanyal et al., 2009;Watanabe et al., 2006; Zhang et al., 2006),
HNF-4a (* revealed by impact of MODY mutations in humans [Vaxillaire
and Froguel, 2008] and pancreatic knockouts in mice [Gupta et al.,
2005; Miura et al., 2006]), VDR (Takiishi et al., 2010), TRb (Amorim
et al., 2009; Bryzgalova et al., 2008a), LRH-1 (Lee et al., 2011), LXRa/
b (Cao et al., 2003; Commerford et al., 2007; Grefhorst et al., 2005;
Herzog et al., 2007; Laffitte et al., 2003; Liu et al., 2006), NR4A (Chao
et al., 2009; Pols et al., 2008) (note: NR4A effects are based on induction
or loss of receptor expression rather than ligand responses).
Figure 1. Proposed Model for McGarry’s Lipogenic Vicious Cycle,
and Its Reversal
In the red, counterclockwise cycle, insulin resistance generates a self-
reinforcing negative regulatory loop in which elevated insulin levels increase
SREBP-1c expression and steatosis. This further decreases insulin sensitivity
and increases in serum insulin levels to continue the negative cycle. Several
NRs, including ERa CAR, LRH-1 TRb, and FXR/SHP, act to decrease
SREBP-1c expression, lowering steatosis and setting up a positive, anti-
lipogenic cycle to improved insulin sensitivity.
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of type 2 diabetes (McGarry, 1992). The crux of his argument was
that the elevation of insulin levels in the early stages of insulin
resistance results in increased lipogenesis and lipid deposi-
tion. This results in increased insulin resistance that drives
insulin levels yet higher, resulting overall in a self-reinforcing
vicious cycle (Figure 1, counterclockwise, red). Although he
also focused on skeletal muscle and other peripheral tissues,
the tight correlation of hepatic steatosis with insulin resistance
in humans (Fabbrini et al., 2010; Korenblat et al., 2008; Petersen
et al., 2005; Samuel et al., 2010) suggests a central role for the
liver in his basic proposal. In accord with this, increased lipogen-
esis contributes significantly to the elevated liver triglycerides in
insulin resistant human subjects with nonalcoholic fatty liver
disease (Donnelly et al., 2005).
McGarry was very aware of the lipogenic impact of insulin, but
his mechanistic views were based on acute allosteric effects on
metabolic pathways and the Randle cycle. Only a year after his
commentary appeared, however, his University of Texas South-
western Medical Center colleagues Michael Brown and Joe
Goldstein (Briggs et al., 1993), and also Bruce Spiegelman
([Tontonoz et al., 1993] as ADD1), first described the transcrip-
tion factor SREBP-1c, which we now know drives the lipogenic
response to insulin in the liver (Horton et al., 2002). Much more
recently, Brown and Goldstein described a mechanism that
could explain the seemingly paradoxical observations that the
insulin resistant liver loses the ability to shut down gluconeogen-
esis in response to elevated insulin levels, while at the same time
maintaining elevated SREBP-1c expression (Brown and Gold-616 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.stein, 2008; Li et al., 2010). They identified a bifurcation in the
insulin signaling pathway in which the induction of lipogenesis,
but not the gluconeogenic response, is under the control of the
mTOR pathway. Thus, the mTOR inhibitor rapamycin blocked
SREBP-1c induction in response to insulin, but did not pre-
vent insulin suppression of PEPCK expression. Both responses
were blocked by the PI3kinase/AKT inhibitor wortmannin,
placing this early target in the insulin signaling cascade up-
stream of the divergent mTORC1-SREBP-1c and FoxO1-
PEPCK branches.
Despite the insulin resistance of the gluconeogenic arm,
persistently elevated SREBP-1c expression in response to
hyperinsulinemia, or potentially other signals (Ferre´ and Foufelle,
2010), could neatly account for the induction of lipogenesis and
increased hepatic steatosis in insulin resistant liver. Consistent
with this, elevated expression of SREBP-1c and its downstream
lipogenic targets is positively correlated with insulin resistance in
subjects with steatosis (Pettinelli et al., 2009). Expression of
SREBP-1c and its targets was also markedly elevated in the
livers of morbidly obese, hyperinsulinemic human patients prior
to gastric bypass, relative to the patients who experienced
massive weight loss and reversal of insulin resistance after
bypass (Elam et al., 2010).
The involvement of mTOR in SREBP-1c activation and steato-
sis in response to western-diet feeding in mice was confirmed in
liver specific knockouts of raptor, the defining mTORC1 com-
ponent (Peterson et al., 2011). Increases in both hepatic triglyc-
erides and the SREBP-1c target fatty acid synthase (FAS) in
response to the diet were completely absent in these Li-RapKO
mice. However, mTORC1 activation is not sufficient to drive
SREBP-1c activation and steatosis. Thus, recent results demon-
strate that the loss of Akt2 in the liver of refed mice prevents the
induction of lipogenesis by refeeding, despite activation of
the mTORC1-SREBP-1c pathway (Wan et al., 2011). Moreover,
the constitutive, insulin independent activation of mTORC1 in
liver specific knockouts of the inhibitor Tsc1 blocks, rather
than promotes, SREBP-1c activation and steatosis (Yecies
et al., 2011). In accord with the Akt2 knockout results, this block
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of Akt2. These results suggest that Akt has additional down-
stream lipogenic targets, and raise interesting questions about
the relationship of the mTOR and Akt pathways to the LXRs,
which are required for insulin dependent activation of SREBP-1c
(Repa et al., 2000), and also directly target downstream lipogenic
genes (Kalaany and Mangelsdorf, 2006).
In McGarry’s vicious cycle, inappropriate activation of
SREBP-1c in the context of insulin resistance drives lipogenesis
and fatty liver, which is then linked to further increases in insulin
resistance. Fatty liver is now widely recognized as a con-
sequence of insulin resistance (Abdelmalek and Diehl, 2007;
Malhi and Gores, 2008). Nonetheless, it is also quite clear from
a number of rodent models (Anstee and Goldin, 2006; Lan
et al., 2003; Monetti et al., 2007), as well as some human exam-
ples (Amaro et al., 2010; Romeo et al., 2008) that simply elevating
liver triglycerides is not sufficient to produce insulin resistance.
The intriguing phenomenon of obese but metabolically normal
individuals (Pataky et al., 2010) is consistent with this, although
there is evidence that such individuals have markedly lower liver
fat than those who are obese and insulin resistant (Stefan et al.,
2008).
Nonetheless, many of the cases in which liver triglycerides are
dissociated from insulin resistance represent unusual genetic
variations, or situations that may not reflect more normal physi-
ology or pathophysiology, and could be considered exceptions
to the general pattern. Thus, there is no doubt that human pop-
ulation studies demonstrate a strong correlation of increased
steatosis with insulin resistance (Fabbrini et al., 2010; Korenblat
et al., 2008; Samuel et al., 2010), which is independent of body
weight (Seppa¨la¨-Lindroos et al., 2002), and various high-fat or
hypercaloric diets reproducibly induce both steatosis and insulin
resistance in rodent models, which is associated with increased
SREBP-1c expression (Biddinger et al., 2005; Shimomura et al.,
1999). In the opposite direction, fasting serum glucose was
normalized in human subjects with type 2 diabetes after the
loss of only a small amount of body weight, and this was corre-
lated with a marked decrease in intrahepatic lipid content but no
effect on peripheral glucose uptake (Petersen et al., 2005).
Improved insulin sensitivity in response to decreased steatosis
is also observed in numerous mouse models (Tilg and Moschen,
2008), including those described below.
One relatively simple resolution of this apparent paradox is
that triglyceride accumulation is not by itself the cause of the
metabolic imbalance initiated by insulin resistance, but is rather
a symptom or an associated comorbidity. In this scenario, lipid
metabolism could somehow be balanced in the exceptional
cases, perhaps by detoxification of free fatty acids via incorpo-
ration into triglycerides (Choi and Diehl, 2008) or sequestration
of lipids into stable droplets (Greenberg et al., 2011), while other
lipids or signaling molecules would drive metabolic imbalance in
the context of insulin resistance. The simplest ‘‘culprit’’ might be
free fatty acids, which are elevated via increased lipolysis in
insulin resistance and are, of course, also the immediate prod-
ucts of lipogenesis. Elevated levels of free fatty acids are associ-
ated with insulin resistance in the liver and also in peripheral
tissues (Boden, 2011). In accord with this, plasma free fatty acids
were higher in individuals with type 2 diabetes and fatty liver than
in diabetics who did not show evidence for fatty liver, and thiselevation was associated with increased insulin resistance
(Kelley et al., 2003). A more recent study of both normal subjects
and those with type 2 diabetes found correlations of elevated
liver fat and free fatty acids with the worsening of many meta-
bolic parameters, including fasting plasma glucose and insulin
levels, hepatic insulin resistance index, and, in the euglycemic
clamp, decreased glucose clearance (Gastaldelli et al., 2007).
There are a number of other candidates in addition to free fatty
acids, including diacylglycerol (Samuel et al., 2010), ceramides
(Haus et al., 2009; Holland and Summers, 2008; Yang et al.,
2009), and hepatic cytokines (Cai et al., 2005; Solinas et al.,
2007), all of which are known to be increased in the context
of steatosis. Inappropriately elevated hepatic production and
serum accumulation of any of these known insulin signaling
inhibitors could contribute to whole body insulin resistance.
I suggest that inhibition of SREBP-1c is a common mecha-
nistic thread that connects at least a subset of the antidiabetic
effects in Table 1. This thread is particularly evident in our recent
studies on the insulin sensitizing effects of agonist ligands for the
nuclear receptors CAR (Dong et al., 2009) and LRH-1 (Lee et al.,
2011). We demonstrated that CAR activation can account for the
insulin sensitizing effects of phenobarbital first described by
Sotaniemi and colleagues in human patients (Lahtela et al.,
1985; Sotaniemi and Karvonen, 1989), and also in ob/ob mice
(Karvonen et al., 1989). A similar impact of CAR activation was
observed independently by Xie and colleagues (Gao et al.,
2009). We also found that a novel LRH-1 agonist, dilauroyl phos-
phatidylcholine, exerts antidiabetic effects in mice that are
strikingly similar to those of phenobarbital. In particular, activa-
tion of either nuclear receptor repressed expression of SREBP-1
messenger RNA, as well as that of its downstream lipogenic
targets including fatty acid synthase, stearoyl CoA desaturase-1,
and acetyl CoA carboxylase. In addition to the decrease in lipo-
genesis expected from these responses, we showed that CAR
activation also increases fatty acid b oxidation (Dong et al.,
2009). This is likely due to decreased malonyl-CoA, the product
of acetyl CoA carboxylase, which McGarry showed is a potent
inhibitor of fatty acid uptake into mitochondria via the carnitine
dependent shuttle (McGarry and Foster, 1980). The net result
in both cases is a striking decrease in hepatic steatosis, but
not overall body weight, which is associated with improved
whole body insulin sensitivity. The lack of significant expression
of either CAR or LRH-1 in other key metabolic target tissues,
particularly skeletal muscle and adipose (Bookout et al., 2006),
and the loss of the LRH-1 response in liver specific knockouts
(Lee et al., 2011) highlight the central role of the liver in both anti-
diabetic effects.
TRb is the best studied of at least three other antidiabetic
nuclear receptors that also repress SREBP-1c. Activation of
both thyroid hormone receptor isoforms in hyperthyroidsm
decreases insulin sensitivity in humans (Dimitriadis et al., 1985).
However, selective liver/TRb activation decreases serum triglyc-
erides and cholesterol in both rodent models and humans
(Angelin and Rudling, 2010). A number of studies show that
SREBP-1c expression is repressed by activation of TRb via T3,
or by the selective agonists GC-1, KB-141, MB07344, and
MB07811 (Angelin and Rudling, 2010; Bryzgalova et al., 2008a;
Erion et al., 2007). This is thought to be due to direct repres-
sion of SREBP-1c promoter activity (Hashimoto et al., 2006;Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 617
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have primarily focused on their effects on serum lipids and body
weight, KB-141 decreased hepatic triglycerides and improved
insulin sensitivity in ob/ob mice (Bryzgalova et al., 2008a), and
both KB-141 and MB07811 repressed SREBP-1c expression
and decreased hepatic triglycerides and serum glucose in the
diet induced obesity mouse model of insulin resistance (Erion
et al., 2007). In both of these studies, the antidiabetic effects
were also correlated with decreased body weight.
The impact of FXR on insulin resistance appears complex, as
noted above, but FXR activation can have positive effects
(Cipriani et al., 2010; Sanyal et al., 2009; Watanabe et al.,
2006; Zhang et al., 2006). Auwerx and collaborators attributed
the beneficial effects of modestly elevated bile acids to suppres-
sion of SREBP-1c expression via induction of the nuclear re-
ceptor corepressor SHP (Watanabe et al., 2004). In human
subjects with nonalcoholic fatty liver disease, increased expres-
sion of SREBP-1c and its downstream lipogenic targets was
recently correlated with decreased FXR expression (Yang
et al., 2010).
Estrogen also has well-established antidiabetic effects in
women (Mauvais-Jarvis, 2011). Studies in rodent models indi-
cate that estradiol suppresses hepatic expression of SREBP-1c
or its downstream targets (Bryzgalova et al., 2008b; Paquette
et al., 2008). This could be linked to its ability to induce SHP
(Gao et al., 2008), or the reported ability of ERb selective ligands
to suppress expression of the site 1 protease required for SREBP
activation in the endoplasmic reticulum (Shin et al., 2007).
Finally, a report suggesting that hepatic Nur77 overexpression
suppresses SREBP-1c activity (Pols et al., 2008), and another
indicating that a general Nur77 knockout increases steatosis
and insulin resistance in high fat-fed mice (Chao et al., 2009)
raise the possibility that this common threadmay extend to other
nuclear receptors.
I propose that the antidiabetic effects of these diverse nuclear
receptor ligands reverse McGarry’s vicious cycle (Figure 1,
clockwise, green). In this ‘‘reverse McGarry effect,’’ the inversion
of that pathologic response generates a positive cycle that is
also self-reinforcing. This starts with direct suppression of
SREBP-1c expression, which decreases steatosis and improves
insulin sensitivity. This results in decreased insulin levels and
a further decrement in SREBP-1c expression, followed by further
improvements in steatosis and insulin resistance that reinforce
the decrease in SREBP-1c (Figure 1, clockwise, green). From
this perspective, the loss of metabolic balance that is initiated
by insulin resistance in McGarry’s vicious cycle is restored by
its equally self-reinforcing reversal.
A prediction of this model is that inhibiting SREBP-1c expres-
sion via other avenues should suppress steatosis and improve
insulin sensitivity. Total (Yahagi et al., 2002) or selective (Moon
et al., 2012) SREBP-1c knockout in ob/ob mice resulted in
decreased steatosis but did not improve insulin sensitivity.
However, interpretation of the phenotypic consequences of
these knockouts is complicated by a compensatory increase in
hepatic SREBP-2 expression (Liang et al., 2002; Shimano
et al., 1997). Consistent with this, inactivation of both SREBP-
1a/c and SREBP-2 by liver-specific knockout of SCAP, which
is required for processing and activation of all three isoforms,
decreased liver triglycerides further (Moon et al., 2012). This618 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.more extreme double SREBP knockout also did not improve
insulin sensitivity, perhaps due to increased lipogenesis in adi-
pose and other tissues in response to the near total loss of
hepatic lipogenesis in the SCAP deficient mice (Moon et al.,
2012).
In contrast, a number of other studies have linked beneficial
effects on both steatosis and glucose homeostasis to more
modest inhibition of SREBP-1c. For example, hepatic overex-
pression of the suppressors of cytokine signaling SOCS-1 and
SOCS-3 in normal chow fed mice is sufficient to induce both
whole body insulin resistance and steatosis, which is linked to
increasing SREBP-1c expression (Ueki et al., 2004). In contrast,
antisense knockdown of the elevated expression of SOCS-3 in
db/db mice normalized the increased expression of SREBP-1c,
and dramatically improved hepatic steatosis and insulin sensi-
tivity (Ueki et al., 2004). PGC-1 reportedly coactivates the ability
of SREBP-1c to induce its own expression (Lin et al., 2005), and
the improvements in both steatosis and whole body insulin
sensitivity that resulted from knockdown of hepatic PGC-1a
expression were attributed to decreased SREBP-1c expression
(Nagai et al., 2009). In a very different model, based on the fact
that SREBP-1c activation depends on the same regulated intra-
membrane proteolytic pathway that is activated by endoplasmic
reticulum stress, overexpression of the chaperone GRP78 in ob/
ob mouse liver decreased SREBP-1c expression and steatosis,
and improved overall insulin sensitivity (Kammoun et al., 2009).
In addition to the effects of nuclear receptor ligands, a number
of other pharmacologic interventions have been described in
which improved metabolic outcomes are linked with decreased
SREBP-1c expression (e.g., Del Bas et al., 2008; Kim et al., 1999;
Li et al., 2011; Park et al., 2008; Ponugoti et al., 2010). Many are
natural products, raising issues regarding specificity and mech-
anism of action. Others, such as metformin, are much better
characterized. However, while metformin and the more specific
AMP kinase activator AICAR clearly lower the expression of
SREBP-1c (Zhou et al., 2001), they exert many other effects
that presumably also contribute to their well-known metabolic
effects. Finally, and in accord with the proposed role of the
mTOR pathway in lipogenesis, rapamycin inhibits the acute
activation of SREBP-1c expression in response to insulin and
refeeding (Li et al., 2010; Yecies et al., 2011). In one study of
high fat-fed mice, chronic rapamycin treatment decreased stea-
tosis and lowered serum insulin levels (Chang et al., 2009).
However, mTOR has additional and complex effects on insulin
signaling and other pathways, and other rapamycin studies
have indicated deleterious results (Fraenkel et al., 2008; Houde
et al., 2010). Rapamycin treatment for immunosuppression in
human patients is associated with hyperlipidemia and glucose
intolerance (Stallone et al., 2009).
More broadly, the focus here on this hepatocentric mecha-
nism is not meant to discount the fundamental impact of adipose
tissue inflammation or other mechanisms in the development of
insulin resistance and diabetes (Hotamisligil, 2006; Shoelson
et al., 2006). In addition, it is apparent that this mechanism
cannot account for all of the antidiabetic effects of nuclear
receptor agonists. PPARg agonists primarily target adipocytes,
and potentially macrophages, although this may result in a less
direct impact on steatosis that could contribute to their insulin
sensitizing effects (Lehrke and Lazar, 2005; Olefsky and Glass,
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b agonists directly induce fatty acid b oxidation in multiple
tissues (Barish et al., 2006), although this could also decrease
steatosis and contribute indirectly to insulin sensitivity. Potential
effects of vitamin D may be due to its anti-inflammatory actions
(Takiishi et al., 2010), and the NR4A receptors may directly regu-
late expression of glucose homeostatic genes in skeletal muscle
and other tissues (Pearen and Muscat, 2010). The most obvious
exception, as noted above, is the antidiabetic effects of LXR
agonists (Cao et al., 2003; Commerford et al., 2007; Grefhorst
et al., 2005; Herzog et al., 2007; Laffitte et al., 2003; Liu et al.,
2006), which are based on other pathways that somehow over-
come their well-known ability to induce SREBP-1c. Finally,
based on the very different physiologic functions of the antidia-
betic nuclear receptors that exhibit the reverse McGarry effect,
it is apparent that each must have additional targets and func-
tions, notably the effects of TRb selective agonists on body
weight, and the ability of Nur77 and the other NR4A members
to increase hepatic glucose output (Pearen and Muscat, 2010).
Thus, other pleiotropic activities of these receptors may be just
as important—or in some cases even more important—than
the inhibition of lipogenesis in mediating their antidiabetic
effects.
Overall, however, it is apparent that inhibition of SREBP-1c
expression is a common thread that connects the antidiabetic
effects of a surprising number of nuclear hormone receptors.
As McGarry said, ‘‘According to this formulation, hyperinsuline-
mia is an early event and serves to drive hepatic lipogenesis and
VLDL synthesis.. The progress of these events leads from
simple insulin resistance to glucose intolerance with elevated
glucose levels causing even greater postprandial hyperinsuline-
mia, which sets up a vicious cycle.’’ Repressing SREBP-1c to run
McGarry’s vicious cycle backward, via nuclear receptor activa-
tion or other strategies, is an attractive approach to treating
steatosis and type 2 diabetes.ACKNOWLEDGMENTS
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